Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Trevena Inc.
Headquarters: Chesterbrook, PA, United States of America
Website: https://www.trevena.com/
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Carrie L. Bourdow, MBA
Number Of Employees: 23
Enterprise Value: $12,465,951
PE Ratio: -0.03
Exchange/Ticker 1: Pink:TRVN
Exchange/Ticker 2: N/A
Latest Market Cap: $1,122,900
BioCentury | Jul 2, 2024
Management Tracks
Patricia Drake to lead commercial at Innoviva’s specialty unit
Plus: Thomas Mehrling name CEO of Swiss biotech Release, and Tenaya CSO Hoey stepping down
BioCentury | Jan 7, 2022
Product Development
ACTIV PPP to deliver more COVID therapy data in 2022
The ACTIV adaptive master protocols are testing a range of COVID-19 therapeutic candidates
BioCentury | Sep 11, 2021
Management Tracks
New CEO for Eden following conviction of JHL execs
Plus: Mavilio, Loggia join Orchard and updates from PMV, Verseau, Apexigen, VectivBio, Protagonist and more
BioCentury | Sep 8, 2021
Management Tracks
Exelixis executives Schwab, Berndt pass away
Plus: bluebird, ADC, Passage Bio and Insilico
BioCentury | Aug 13, 2020
Regulation
Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more
FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53
BioCentury | Jul 25, 2020
Management Tracks
New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more
BioCentury | Mar 10, 2020
Product Development
March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi
BioCentury | Feb 29, 2020
Management Tracks
Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,
BioCentury | Aug 28, 2019
Company News
Aug. 28 Company Quick Takes: Amgen to appeal Repatha ruling and EcoR1 buys Woodford’s stake in Prothena; plus DarwinHealth-Celgene, CRISPR IP, Trevena and Shink
BioCentury | Jun 28, 2019
Company News
Management tracks: Gottlieb joins Pfizer board; plus Adaptimmune, Xencor, Arcus and more
Items per page:
1 - 10 of 106